MarginsXMarginsX
Home › Markets › Health Care › VSTM

Verastem Inc. (VSTM)

VSTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.70
-5.87% on the day
Market cap
$970.3M
Small cap
Revenue · 2025
$30.9M
+209.1% on 2024
Net income · 2025
-$209.5M
-677.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/0001104659-26-023444-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVSTM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2012
SEC CIK0001526119
SEC industry codePharmaceutical Preparations
Incorporated inMA

Financials · 2025

LineValue
Revenue$30.9M
Net income-$209.5M
Operating income-$170.1M
Net margin-677.6%
Operating margin-550.3%
Revenue growth+209.1%
Cash$205.0M
Total assets$246.4M
P/E (computed)Net income was not positive
P/S (computed)31.4×

Warning signs

Cash runway
13.0 months
$172.8M cash at September 30, 2026
Share count, 1 year
+88.7%
2025-11-03 to 2026-11-02 · +398.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$788K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As of June 30, 2026, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to anticipated operating losses for the foreseeable future."
10-Q 2026-11-05
Cash and burn$172.8M cash; operating cash flow -$39.9M a quarter.Report 2026-09-30
Shares outstanding126,014,804 (2026-11-02); 66,776,006 a year earlier; 25,267,436 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-10-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $788K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$24.0M-$74.7M-$33.6M$172.8MNo debt tags$100.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$40.1M-$34.7M-$43.9M$136.4M$214K$87.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$18.7M-$36.6M-$52.1M$165.6M$529K$49.6M10-Q 2026-05-07
Q4 2025
2025-12-31
$17.5M-$32.9M-$30.0M$205.0MNo debt tags$30.9M10-K 2026-03-04
Q3 2025
2025-09-30
$11.2M-$98.5M-$36.2M$137.7M$188KNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
$2.1M-$25.9M-$32.7M$164.3M$467KNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$52.1M-$38.7M$117.6M$740KNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
$0-$64.6M-$25.1M$88.8M$40.7M$10.0M10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-05
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEF 14A2026-04-09

Source: SEC EDGAR submissions feed, 1,007 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.7%
1 month+9.8%
3 months+22.6%
Year to date+6.0%
1 year+0.9%
From 52-week high-23.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
SVRASavara Inc.$4.46-3.77%$985.1M
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
CYRXCryoPort Inc.$19.80-0.45%$1.0B
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
AKTSAktis Oncology Inc.$16.16-2.77%$901.7M
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
CRVSCorvus Pharmaceuticals Inc.$10.60-0.38%$894.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier